@article{3102725,
    title = "Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†",
    author = "Dimopoulos, M.A. and Moreau, P. and Terpos, E. and Mateos, M.V. and Zweegman, S. and Cook, G. and Delforge, M. and Hájek, R. and Schjesvold, F. and Cavo, M. and Goldschmidt, H. and Facon, T. and Einsele, H. and Boccadoro, M. and San-Miguel, J. and Sonneveld, P. and Mey, U. and EHA Guidelines Committee and ESMO Guidelines Committee",
    journal = "Annals of Oncology",
    year = "2021",
    volume = "32",
    number = "3",
    pages = "309-322",
    publisher = "Elsevier Ireland Ltd",
    issn = "0923-7534, 1569-8041",
    doi = "10.1016/j.annonc.2020.11.014",
    keywords = "antineoplastic agent;  bortezomib;  busulfan;  carfilzomib;  cyclophosphamide;  dexamethasone;  doxorubicin;  lenalidomide;  melphalan;  prednisone;  thalidomide, Article;  autologous stem cell transplantation;  cancer diagnosis;  cancer incidence;  cancer radiotherapy;  cancer staging;  cancer survival;  cancer therapy;  consolidation chemotherapy;  differential diagnosis;  epidemiological data;  follow up;  graft versus host reaction;  human;  long term care;  maintenance therapy;  multiple myeloma;  personalized medicine;  plasma cell leukemia;  plasmacytoma;  practice guideline;  relapse;  risk benefit analysis;  treatment response;  follow up;  medical society;  multiple myeloma;  practice guideline, Follow-Up Studies;  Humans;  Multiple Myeloma;  Societies, Medical"
}